Do you want to read an article? Please log in or register.
Durvalumab plus platinum-etoposide in the first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): A single-arm clinical trial
Lung Cancer
Related content
Lung Cancer
Durvalumab, carboplatin, and etoposide in patients who are treatment-naive with extensive-stage small-cell lung cancer and poor performance status (NEJ045A): a single-arm phase 2 trial
Lancet Respir Med
Asao T, Saida Y, Watanabe S, Kisohara A, Kishi K, Morita R, Nakagawa T, Tsukita Y, Furuya N, Miyawaki T, Ishikawa N, Yamada T, Tanaka T, Morita S, Kikuchi T, Maemondo M, Kobayashi K, North East Japan Study Group
doi: 10.1016/S2213-2600(25)00240-1
RECOMMENDED
Lung Cancer
The PESGA Trial: A Prospective, Open-Label, Single-Arm, Phase II Study to Evaluate First Line Therapy for Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Patients, Treated by Induction Carboplatin/Etoposide/Pembrolizumab Followed by Maintenance of Pembrolizumab/ Sacituzumab Govitecan
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Clin Lung Cancer
Roisman LC, Mann S, Basel A, Marei R, Krayim B, Kornev G, Asna N, Peled N
doi: 10.1016/j.cllc.2025.02.002
Lung Cancer
Durvalumab Plus Platinum-Etoposide in Extensive-Stage Small-Cell Lung Cancer: Outcomes in Age, Sex, and Platinum Subgroups From the Phase 3 CASPIAN Study
Clin Lung Cancer
Reinmuth N, Goldman JW, Chen Y, Hotta K, Trukhin D, Statsenko G, Hochmair M, Özgüroğlu M, Ji JH, Garassino MC, Poltoratskiy A, Verderame F, Havel L, Bondarenko I, Losonczy G, Conev N, Kummer S, Mann H, Chugh P, Dalvi T, Paz-Ares L
doi: 10.1016/j.cllc.2025.08.001
RECOMMENDED
Lung Cancer
The Italian Mauris Phase IIIb Trial of Atezolizumab Plus Carboplatin and Etoposide for Patients With Newly Diagnosed Extensive-Stage Small Cell Lung Cancer: 3-Year End-of-Study Results
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Clin Lung Cancer
Morgillo F, Del Signore E, Bria E, de Marinis F, Ciardiello F, Garassino MC, Stefani A, Verderame F, Morabito A, Sbrana A, Tonini G, Gilli M, Berardi R, Taveggia PA, Bearz A, Delmonte A, Migliorino MR, Gridelli C, Fadda GM, Iero M, Ardizzoni A
doi: 10.1016/j.cllc.2025.07.003
RECOMMENDED
Lung Cancer
An open-label, randomized phase III study of early switch maintenance vs delayed second-line nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-line platinum-based chemotherapy-EDEN trial GOIRC 04-2016
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Lung Cancer
Gelsomino F, Boni L, Tiseo M, Ricciardi S, Rocco D, Cortinovis DL, Proietto M, Cogoni A, Pasello G, Camerini A, Sperandi F, Colantonio I, Metro G, Mazzoni F, Baldini E, Veccia A, Bennicelli E, Cecilia Bettini A, Tognetto M, Ardizzoni A
doi: 10.1016/j.lungcan.2024.108059
Lung Cancer
Real-world comparison of the efficacy and safety of atezolizumab versus durvalumab in extensive-stage small cell lung cancer
Lung Cancer
Vince M, Naqvi SMH, Pellini B, Verbosky M, Melzer D
doi: 10.1016/j.lungcan.2024.107999
Lung Cancer
Efficacy of immune checkpoint inhibitors plus platinum-based chemotherapy as 1st line treatment for patients with non-small cell lung cancer harboring HER2 mutations: Results from LC-SCRUM-Asia
Lung Cancer
Kato Y, Udagawa H, Matsumoto S, Izumi H, Ohe Y, Kato T, Nishino K, Miyamoto S, Kawana S, Chikamori K, Shingyoji M, Sato Y, Takada Y, Toyozawa R, Azuma K, Tanaka Y, Sakai T, Shibata Y, Sugiyama E, Nosaki K, Zenke Y, Umemura S, Yoh K, Seike M, Goto K
doi: 10.1016/j.lungcan.2024.107992
RECOMMENDED
Lung Cancer
Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08-2015 ENERGY): a randomised, open-label, phase 3 study
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Lancet Respir Med
Léna H, Greillier L, Cropet C, Bylicki O, Monnet I, Audigier-Valette C, Falchero L, Vergnenègre A, Demontrond P, Geier M, Guisier F, Hominal S, Locher C, Corre R, Chouaid C, Ricordel C, GFPC 08–2015 ENERGY investigators
doi: 10.1016/S2213-2600(24)00264-9
RECOMMENDED
Lung Cancer
Neoadjuvant Aumolertinib for unresectable stage III EGFR-mutant non-small cell lung cancer: a single-arm phase II trial
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Nat Commun
Bian D, Ji S, Liu Y, Huang Z, Jiang L, Liu M, Bao X, Yang J, Zhou Y, Hu J, Sun L, Zheng Y, Huang J, Liu J, Zhu X, Zhang J, Zhang L, Liu X, He W, Xie D, Zhu Y, Wu C, Zhao D, Duan L, Jiang G, Zhang P
doi: 10.1038/s41467-025-58435-9